A composition for oral use in the solid form of a suckable and/or melt-in-mouth and/or mouth dissolving tablet or the like, comprising: I) a mixture which comprises or, alternatively, consists of: - a hyaluronic acid, or a salt thereof, and - a chondroitin, or a salt thereof and, optionally, - a basic substance with antacid properties selected from the group comprising or, alternatively, consisting of a salt of a cation of an alkali metal or of a cation of an alkaline earth metal or of a cation of a metal, wherein said salt is in the form of an oxide, a hydroxide, a carbonate, a bicarbonate, a silicate, a trisilicate, a sulphate or a citrate, and, optionally, - a proton pump inhibitor compound -PPI selected from the group comprising or, alternatively, consisting of: omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole sodium, ilaprazole and tenatoprazole; and, optionally, II) at least one food or pharmaceutical grade excipient or additive; said composition being for use: i) in a method for the treatment of disorders or symptoms caused or provoked by gastroesophageal reflux (GERD), or ii) in a method for the treatment of extraesophageal disorders or symptoms caused by the upflow of gastric contents and/or gastric vapours from the stomach to the oral cavity (also known as refluxate, which comprises pepsin, acid and/or mildly acidic or non-acidic but irritating contents), or iii) in a method for the treatment of subjects with ulcers or lacerations provoked in the gastric mucosa (stomach lining), in the esophageal mucosa, in the laryngopharyngeal mucosa or in the tissues lining the oral cavity, so as to protect the mucosa and the tissues from the damage provoked thereto; in subjects in a state of need for said treatments, wherein said subjects have proven to be nonresponsive or poorly responsive to previous treatments carried out by administering alginates, wherein said alginates are preferably sodium alginate or potassium alginate or magnesium alginate. I) a mixture which comprises or, alternatively, consists of: - a hyaluronic acid, or a salt thereof, and - a chondroitin, or a salt thereof and, optionally, - a basic substance with antacid properties selected from the group comprising or, alternatively, consisting of a salt of a cation of an alkali metal or of a cation of an alkaline earth metal or of a cation of a metal, wherein said salt is in the form of an oxide, a hydroxide, a carbonate, a bicarbonate, a silicate, a trisilicate, a sulphate or a citrate, and, optionally, - a proton pump inhibitor compound -PPI selected from the group comprising or, alternatively, consisting of: omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole sodium, ilaprazole and tenatoprazole; and, optionally, - a hyaluronic acid, or a salt thereof, and - a chondroitin, or a salt thereof and, optionally, - a basic substance with antacid properties selected from the group comprising or, alternatively, consisting of a salt of a cation of an alkali metal or of a cation of an alkaline earth metal or of a cation of a metal, wherein said salt is in the form of an oxide, a hydroxide, a carbonate, a bicarbonate, a silicate, a trisilicate, a sulphate or a citrate, and, optionally, - a proton pump inhibitor compound -PPI selected from the group comprising or, alternatively, consisting of: omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole sodium, ilaprazole and tenatoprazole; II) at least one food or pharmaceutical grade excipient or additive; said composition being for use: i) in a method for the treatment of disorders or symptoms caused or provoked by gastroesophageal reflux (GERD), or ii) in a method for the treatment of extraesophageal disorders or symptoms caused by the upflow of gastric contents and/or gastric vapours from the stomach to the oral cavity (also known as refluxate, which comprises pepsin, acid and/or mildly acidic or non-acidic but irritating contents), or iii) in a method for the treatment of subjects with ulcers or lacerations provoked in the gastric mucosa (stomach lining), in the esophageal mucosa, in the laryngopharyngeal mucosa or in the tissues lining the oral cavity, so as to protect the mucosa and the tissues from the damage provoked thereto; in subjects in a state of need for said treatments, wherein said subjects have proven to be nonresponsive or poorly responsive to previous treatments carried out by administering alginates, wherein said alginates are preferably sodium alginate or potassium alginate or magnesium alginate. i) in a method for the treatment of disorders or symptoms caused or provoked by gastroesophageal reflux (GERD), or ii) in a method for the treatment of extraesophageal disorders or symptoms caused by the upflow of gastric contents and/or gastric vapours from the stomach to the oral cavity (also known as refluxate, which comprises pepsin, acid and/or mildly acidic or non-acidic but irritating contents), or iii) in a method for the treatment of subjects with ulcers or lacerations provoked in the gastric mucosa (stomach lining), in the esophageal mucosa, in the laryngopharyngeal mucosa or in the tissues lining the oral cavity, so as to protect the mucosa and the tissues from the damage provoked thereto;